Published in F1000Prime Rep on May 12, 2015
Bortezomib in Late Antibody-mediated Kidney Transplant Rejection (BORTEJECT) | NCT01873157
Bortezomib in Rejection of Kidney Transplants (TRIBUTE) | NCT02201576
The Immunogenicity of HLA Class II Mismatches: The Predicted Presentation of Nonself Allo-HLA-Derived Peptide by the HLA-DR Phenotype of the Recipient Is Associated with the Formation of DSA. J Immunol Res (2017) 0.75
Effect of Immunosuppressive Drugs on Humoral Allosensitization after Kidney Transplant. J Am Soc Nephrol (2016) 0.75
Soothing touch of CD31 protects endothelium during cellular immune responses. Proc Natl Acad Sci U S A (2015) 0.75
Endothelial Cells in Antibody-Mediated Rejection of Kidney Transplantation: Pathogenesis Mechanisms and Therapeutic Implications. J Immunol Res (2017) 0.75
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 6.31
Significance of the positive crossmatch test in kidney transplantation. N Engl J Med (1969) 5.50
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol (2007) 4.96
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med (2005) 4.84
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant (2011) 4.06
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol (2002) 3.34
Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med (2000) 3.25
Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant (2009) 3.19
Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med (2001) 3.10
Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol (2010) 2.66
Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol (2008) 2.52
Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med (2010) 2.28
Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant (2009) 2.27
A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant (2011) 2.16
Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant (2011) 1.98
Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int Suppl (2005) 1.96
Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int (1993) 1.80
Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation (2003) 1.80
Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J Am Soc Nephrol (2014) 1.78
Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant (2012) 1.78
Humoral antibodies in renal allotransplantation in man. N Engl J Med (1970) 1.74
Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol (2001) 1.72
One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial. Transplantation (2016) 1.68
Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant (2009) 1.67
No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation (2011) 1.67
Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation (2008) 1.66
Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant (2011) 1.66
NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant (2010) 1.62
Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant (2012) 1.60
Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J Am Soc Nephrol (2014) 1.60
Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int (2010) 1.57
Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant (2009) 1.52
Complement is activated by IgG hexamers assembled at the cell surface. Science (2014) 1.52
Solid phase detection of C4d-fixing HLA antibodies to predict rejection in high immunological risk kidney transplant recipients. Transpl Int (2012) 1.50
To biopsy or not to biopsy? Should we screen the histology of stable renal grafts? Transplantation (2007) 1.49
Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and "antibodyome" measures. Proc Natl Acad Sci U S A (2009) 1.47
Kidney intragraft donor-specific antibodies as determinant of antibody-mediated lesions and poor graft outcome. Am J Transplant (2013) 1.47
Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol (1994) 1.45
Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. Am J Transplant (2013) 1.44
Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation (2007) 1.41
Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant (2008) 1.37
Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation (2005) 1.29
Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant (2007) 1.24
Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice. Am J Transplant (2010) 1.23
Effect of antibodies on endothelium. Am J Transplant (2009) 1.23
The low concentration of macroglobulin antibodies in peripheral lymph. Immunology (1969) 1.19
Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies. Transplantation (2014) 1.16
Non-complement- and complement-activating antibodies synergize to cause rejection of cardiac allografts. Am J Transplant (2004) 1.14
Germinal center alloantibody responses are mediated exclusively by indirect-pathway CD4 T follicular helper cells. J Immunol (2012) 1.08
Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. J Am Soc Nephrol (2011) 1.07
H-Y antibody development associates with acute rejection in female patients with male kidney transplants. Transplantation (2008) 1.07
Chronic rejection triggers the development of an aggressive intragraft immune response through recapitulation of lymphoid organogenesis. J Immunol (2010) 1.05
Regulatory B cells and tolerance in transplantation: from animal models to human. Front Immunol (2013) 1.04
Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. Transplantation (2011) 1.03
The use of eculizumab in renal transplantation. Clin Transplant (2013) 1.00
Enzyme-linked immunoassay for anti-HLA antibodies--an alternative to panel studies by lymphocytotoxicity. Transplantation (1993) 0.99
Immune recognition and rejection of allogeneic skin grafts. Immunotherapy (2011) 0.97
B cells mediate chronic allograft rejection independently of antibody production. J Clin Invest (2014) 0.96
Humoral immunity in chronic allograft rejection: puzzle pieces come together. Transpl Immunol (2011) 0.96
Chronic antibody mediated rejection of renal allografts: pathological, serological and immunologic features in nonhuman primates. Am J Transplant (2006) 0.92
HLA antibody detection with solid phase assays: great expectations or expectations too great? Am J Transplant (2014) 0.92
Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance. Curr Opin Organ Transplant (2013) 0.90
Immunoglobulin isotype-specific characterization of anti-human leukocyte antigen antibodies eluted from explanted renal allografts. Hum Immunol (2007) 0.90
Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant (2006) 0.89
Endothelial cell antibodies associated with novel targets and increased rejection. J Am Soc Nephrol (2014) 0.89
Pathophysiologic significance of B-cell clusters in chronically rejected grafts. Transplantation (2011) 0.87
Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival. Kidney Int (2013) 0.87
Immune responses elicited in tertiary lymphoid tissues display distinctive features. PLoS One (2010) 0.86
The complement interference phenomenon as a cause for sharp fluctuations of serum anti-HLA antibody strength in kidney transplant patients. Transpl Immunol (2013) 0.85
Lymphoid neogenesis in chronic rejection. Curr Opin Organ Transplant (2008) 0.83
Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients. Am J Transplant (2006) 0.83
Direct and indirect effects of alloantibodies link neointimal and medial remodeling in graft arteriosclerosis. Arterioscler Thromb Vasc Biol (2006) 0.82
De novo donor-specific human leukocyte antigen antibodies early after kidney transplantation. Transplantation (2014) 0.80
A stepwise breakdown of B-cell tolerance occurs within renal allografts during chronic rejection. Kidney Int (2011) 0.79
Cytomegalovirus-responsive γδ T cells: novel effector cells in antibody-mediated kidney allograft microcirculation lesions. J Am Soc Nephrol (2014) 0.78
Transplantation: Donor-specific HLA antibodies and renal allograft failure. Nat Rev Nephrol (2013) 0.78
Immunoglobulin G subclass analysis of HLA donor specific antibodies in heart and renal transplant recipients. Clin Transpl (2013) 0.78
Physiological and therapeutic complement regulators in kidney transplantation. Curr Opin Organ Transplant (2013) 0.78
The effect of combination therapy with rituximab and intravenous immunoglobulin on the progression of chronic antibody mediated rejection in renal transplant recipients. J Immunol Res (2014) 0.76
A Systematic Review and Meta-Analysis of Rituximab in Antibody-mediated Renal Allograft Rejection. Int J Organ Transplant Med (2011) 0.76